Loading…
Increased Antiviral Medication Sales Before the 2005–06 Influenza Season — New York City
Oseltamivir, zanamivir, rimantadine, and amantadine are antiviral medications approved for the treatment and/or prophylaxis of influenza A and/or B, although high levels of resistance among circulating strains of influenza A led CDC to issue interim recommendations in January 2005, advising that ama...
Saved in:
Published in: | MMWR. Morbidity and mortality weekly report 2006-03, Vol.55 (10), p.277-279 |
---|---|
Main Authors: | , , , , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | |
container_end_page | 279 |
container_issue | 10 |
container_start_page | 277 |
container_title | MMWR. Morbidity and mortality weekly report |
container_volume | 55 |
creator | Miller, J Schmit, K Duncan, P Waters, C Johnson, G Chang, H Wallace, B Kacica, M Smith, P Das, D Harper, S Heffernan, R Olson, D Nivin, B Weiss, D |
description | Oseltamivir, zanamivir, rimantadine, and amantadine are antiviral medications approved for the treatment and/or prophylaxis of influenza A and/or B, although high levels of resistance among circulating strains of influenza A led CDC to issue interim recommendations in January 2005, advising that amantadine and rimantadine not be used for the treatment or prevention of influenza A during the 2005-06 influenza season. As part of syndromic surveillance, the New York State Department of Health (NYSDOH) monitors sales of antiviral influenza medications paid for by the Medicaid system, and the New York City Department of Health and Mental Hygiene (NYCDOHMH) monitors sales of antiviral influenza medications by a retail pharmacy chain. Syndromic data are used in combination with data provided by laboratories, health-care facilities, and health-care providers to monitor influenza activity. In October 2005, a spike in antiviral medication sales was noted. The spike did not coincide with other markers of influenza activity but did coincide with the beginning of media coverage of avian influenza A (H5N1) and the potential for an influenza pandemic. Tracking prescription medication sales can detect spikes for which no immediate indication exists. Such syndromic data might be used to guide issuance of public health recommendations regarding the limited availability of certain medications and the inadvisability of personal stockpiling. |
format | article |
fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_67756339</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A144294386</galeid><jstor_id>23316882</jstor_id><sourcerecordid>A144294386</sourcerecordid><originalsourceid>FETCH-LOGICAL-g254t-224fe362a56e436cb4dba6197eea15ba3d477ccb1b9d16cddd84d08051c71b823</originalsourceid><addsrcrecordid>eNptkc1O3DAQxyNEBcuWR6DyiVtQ_JnkuKz4WIm2B0BqpUqRY092DVkbbAcEJ96BPuE-Sb1aWhWJmcNIM7_5az62shHmjOeVwD-2s1GBWZ0TXPPdbC-Em2JttNjJdrHgjFYVGWW_ZlZ5kAE0mthoHoyXPfoK2igZjbPoUvYQ0DF0zgOKC0CkKPjq5bUQaGa7fgD7LNFlEkjs6uU3-gaP6Kfzt2hq4tPn7FMn-wD7b3GcXZ-eXE3P84vvZ7Pp5CKfE85iTgjrgAoiuQBGhWqZbqXAdQkgMW8l1awslWpxW2sslNa6YrqoCo5ViduK0HF2uNG98-5-gBCbpQkK-l5acENoRFlyQWmdwHwDztNajbGdi16qOVhIazsLnUnpCWaM1Ok-IvFHH_DJNSyN-rDh8L-GBcg-LoLrh_Utw3vwy9vIQ7sE3dx5s5T-qfn7mQQcbICbEJ3_VyeUYrGu_wHdPJOX</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67756339</pqid></control><display><type>article</type><title>Increased Antiviral Medication Sales Before the 2005–06 Influenza Season — New York City</title><source>JSTOR Archival Journals and Primary Sources Collection</source><source>ProQuest Social Science Premium Collection</source><creator>Miller, J ; Schmit, K ; Duncan, P ; Waters, C ; Johnson, G ; Chang, H ; Wallace, B ; Kacica, M ; Smith, P ; Das, D ; Harper, S ; Heffernan, R ; Olson, D ; Nivin, B ; Weiss, D</creator><creatorcontrib>Miller, J ; Schmit, K ; Duncan, P ; Waters, C ; Johnson, G ; Chang, H ; Wallace, B ; Kacica, M ; Smith, P ; Das, D ; Harper, S ; Heffernan, R ; Olson, D ; Nivin, B ; Weiss, D ; Centers for Disease Control and Prevention (CDC)</creatorcontrib><description>Oseltamivir, zanamivir, rimantadine, and amantadine are antiviral medications approved for the treatment and/or prophylaxis of influenza A and/or B, although high levels of resistance among circulating strains of influenza A led CDC to issue interim recommendations in January 2005, advising that amantadine and rimantadine not be used for the treatment or prevention of influenza A during the 2005-06 influenza season. As part of syndromic surveillance, the New York State Department of Health (NYSDOH) monitors sales of antiviral influenza medications paid for by the Medicaid system, and the New York City Department of Health and Mental Hygiene (NYCDOHMH) monitors sales of antiviral influenza medications by a retail pharmacy chain. Syndromic data are used in combination with data provided by laboratories, health-care facilities, and health-care providers to monitor influenza activity. In October 2005, a spike in antiviral medication sales was noted. The spike did not coincide with other markers of influenza activity but did coincide with the beginning of media coverage of avian influenza A (H5N1) and the potential for an influenza pandemic. Tracking prescription medication sales can detect spikes for which no immediate indication exists. Such syndromic data might be used to guide issuance of public health recommendations regarding the limited availability of certain medications and the inadvisability of personal stockpiling.</description><identifier>ISSN: 0149-2195</identifier><identifier>EISSN: 1545-861X</identifier><identifier>PMID: 16543882</identifier><language>eng</language><publisher>United States: Centers for Disease Control and Prevention</publisher><subject>Anti-infective agents ; Antiviral Agents - supply & distribution ; Antiviral Agents - therapeutic use ; Antivirals ; Commerce ; Drug prescriptions ; Drug Utilization - statistics & numerical data ; Health aspects ; Humans ; Influenza ; Influenza A virus ; Influenza, Human - epidemiology ; Influenza, Human - prevention & control ; Medicaid ; Medications ; New York City - epidemiology ; Pharmacies ; Population Surveillance ; Public health ; Recommendations ; Seasons ; Specimens ; Statistics ; Surveillance</subject><ispartof>MMWR. Morbidity and mortality weekly report, 2006-03, Vol.55 (10), p.277-279</ispartof><rights>COPYRIGHT 2006 U.S. Government Printing Office</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/23316882$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/23316882$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>314,776,780,33589,58213,58446</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16543882$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Miller, J</creatorcontrib><creatorcontrib>Schmit, K</creatorcontrib><creatorcontrib>Duncan, P</creatorcontrib><creatorcontrib>Waters, C</creatorcontrib><creatorcontrib>Johnson, G</creatorcontrib><creatorcontrib>Chang, H</creatorcontrib><creatorcontrib>Wallace, B</creatorcontrib><creatorcontrib>Kacica, M</creatorcontrib><creatorcontrib>Smith, P</creatorcontrib><creatorcontrib>Das, D</creatorcontrib><creatorcontrib>Harper, S</creatorcontrib><creatorcontrib>Heffernan, R</creatorcontrib><creatorcontrib>Olson, D</creatorcontrib><creatorcontrib>Nivin, B</creatorcontrib><creatorcontrib>Weiss, D</creatorcontrib><creatorcontrib>Centers for Disease Control and Prevention (CDC)</creatorcontrib><title>Increased Antiviral Medication Sales Before the 2005–06 Influenza Season — New York City</title><title>MMWR. Morbidity and mortality weekly report</title><addtitle>MMWR Morb Mortal Wkly Rep</addtitle><description>Oseltamivir, zanamivir, rimantadine, and amantadine are antiviral medications approved for the treatment and/or prophylaxis of influenza A and/or B, although high levels of resistance among circulating strains of influenza A led CDC to issue interim recommendations in January 2005, advising that amantadine and rimantadine not be used for the treatment or prevention of influenza A during the 2005-06 influenza season. As part of syndromic surveillance, the New York State Department of Health (NYSDOH) monitors sales of antiviral influenza medications paid for by the Medicaid system, and the New York City Department of Health and Mental Hygiene (NYCDOHMH) monitors sales of antiviral influenza medications by a retail pharmacy chain. Syndromic data are used in combination with data provided by laboratories, health-care facilities, and health-care providers to monitor influenza activity. In October 2005, a spike in antiviral medication sales was noted. The spike did not coincide with other markers of influenza activity but did coincide with the beginning of media coverage of avian influenza A (H5N1) and the potential for an influenza pandemic. Tracking prescription medication sales can detect spikes for which no immediate indication exists. Such syndromic data might be used to guide issuance of public health recommendations regarding the limited availability of certain medications and the inadvisability of personal stockpiling.</description><subject>Anti-infective agents</subject><subject>Antiviral Agents - supply & distribution</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Antivirals</subject><subject>Commerce</subject><subject>Drug prescriptions</subject><subject>Drug Utilization - statistics & numerical data</subject><subject>Health aspects</subject><subject>Humans</subject><subject>Influenza</subject><subject>Influenza A virus</subject><subject>Influenza, Human - epidemiology</subject><subject>Influenza, Human - prevention & control</subject><subject>Medicaid</subject><subject>Medications</subject><subject>New York City - epidemiology</subject><subject>Pharmacies</subject><subject>Population Surveillance</subject><subject>Public health</subject><subject>Recommendations</subject><subject>Seasons</subject><subject>Specimens</subject><subject>Statistics</subject><subject>Surveillance</subject><issn>0149-2195</issn><issn>1545-861X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><recordid>eNptkc1O3DAQxyNEBcuWR6DyiVtQ_JnkuKz4WIm2B0BqpUqRY092DVkbbAcEJ96BPuE-Sb1aWhWJmcNIM7_5az62shHmjOeVwD-2s1GBWZ0TXPPdbC-Em2JttNjJdrHgjFYVGWW_ZlZ5kAE0mthoHoyXPfoK2igZjbPoUvYQ0DF0zgOKC0CkKPjq5bUQaGa7fgD7LNFlEkjs6uU3-gaP6Kfzt2hq4tPn7FMn-wD7b3GcXZ-eXE3P84vvZ7Pp5CKfE85iTgjrgAoiuQBGhWqZbqXAdQkgMW8l1awslWpxW2sslNa6YrqoCo5ViduK0HF2uNG98-5-gBCbpQkK-l5acENoRFlyQWmdwHwDztNajbGdi16qOVhIazsLnUnpCWaM1Ok-IvFHH_DJNSyN-rDh8L-GBcg-LoLrh_Utw3vwy9vIQ7sE3dx5s5T-qfn7mQQcbICbEJ3_VyeUYrGu_wHdPJOX</recordid><startdate>20060317</startdate><enddate>20060317</enddate><creator>Miller, J</creator><creator>Schmit, K</creator><creator>Duncan, P</creator><creator>Waters, C</creator><creator>Johnson, G</creator><creator>Chang, H</creator><creator>Wallace, B</creator><creator>Kacica, M</creator><creator>Smith, P</creator><creator>Das, D</creator><creator>Harper, S</creator><creator>Heffernan, R</creator><creator>Olson, D</creator><creator>Nivin, B</creator><creator>Weiss, D</creator><general>Centers for Disease Control and Prevention</general><general>U.S. Government Printing Office</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20060317</creationdate><title>Increased Antiviral Medication Sales Before the 2005–06 Influenza Season — New York City</title><author>Miller, J ; Schmit, K ; Duncan, P ; Waters, C ; Johnson, G ; Chang, H ; Wallace, B ; Kacica, M ; Smith, P ; Das, D ; Harper, S ; Heffernan, R ; Olson, D ; Nivin, B ; Weiss, D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-g254t-224fe362a56e436cb4dba6197eea15ba3d477ccb1b9d16cddd84d08051c71b823</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Anti-infective agents</topic><topic>Antiviral Agents - supply & distribution</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Antivirals</topic><topic>Commerce</topic><topic>Drug prescriptions</topic><topic>Drug Utilization - statistics & numerical data</topic><topic>Health aspects</topic><topic>Humans</topic><topic>Influenza</topic><topic>Influenza A virus</topic><topic>Influenza, Human - epidemiology</topic><topic>Influenza, Human - prevention & control</topic><topic>Medicaid</topic><topic>Medications</topic><topic>New York City - epidemiology</topic><topic>Pharmacies</topic><topic>Population Surveillance</topic><topic>Public health</topic><topic>Recommendations</topic><topic>Seasons</topic><topic>Specimens</topic><topic>Statistics</topic><topic>Surveillance</topic><toplevel>online_resources</toplevel><creatorcontrib>Miller, J</creatorcontrib><creatorcontrib>Schmit, K</creatorcontrib><creatorcontrib>Duncan, P</creatorcontrib><creatorcontrib>Waters, C</creatorcontrib><creatorcontrib>Johnson, G</creatorcontrib><creatorcontrib>Chang, H</creatorcontrib><creatorcontrib>Wallace, B</creatorcontrib><creatorcontrib>Kacica, M</creatorcontrib><creatorcontrib>Smith, P</creatorcontrib><creatorcontrib>Das, D</creatorcontrib><creatorcontrib>Harper, S</creatorcontrib><creatorcontrib>Heffernan, R</creatorcontrib><creatorcontrib>Olson, D</creatorcontrib><creatorcontrib>Nivin, B</creatorcontrib><creatorcontrib>Weiss, D</creatorcontrib><creatorcontrib>Centers for Disease Control and Prevention (CDC)</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>MMWR. Morbidity and mortality weekly report</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Miller, J</au><au>Schmit, K</au><au>Duncan, P</au><au>Waters, C</au><au>Johnson, G</au><au>Chang, H</au><au>Wallace, B</au><au>Kacica, M</au><au>Smith, P</au><au>Das, D</au><au>Harper, S</au><au>Heffernan, R</au><au>Olson, D</au><au>Nivin, B</au><au>Weiss, D</au><aucorp>Centers for Disease Control and Prevention (CDC)</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Increased Antiviral Medication Sales Before the 2005–06 Influenza Season — New York City</atitle><jtitle>MMWR. Morbidity and mortality weekly report</jtitle><addtitle>MMWR Morb Mortal Wkly Rep</addtitle><date>2006-03-17</date><risdate>2006</risdate><volume>55</volume><issue>10</issue><spage>277</spage><epage>279</epage><pages>277-279</pages><issn>0149-2195</issn><eissn>1545-861X</eissn><abstract>Oseltamivir, zanamivir, rimantadine, and amantadine are antiviral medications approved for the treatment and/or prophylaxis of influenza A and/or B, although high levels of resistance among circulating strains of influenza A led CDC to issue interim recommendations in January 2005, advising that amantadine and rimantadine not be used for the treatment or prevention of influenza A during the 2005-06 influenza season. As part of syndromic surveillance, the New York State Department of Health (NYSDOH) monitors sales of antiviral influenza medications paid for by the Medicaid system, and the New York City Department of Health and Mental Hygiene (NYCDOHMH) monitors sales of antiviral influenza medications by a retail pharmacy chain. Syndromic data are used in combination with data provided by laboratories, health-care facilities, and health-care providers to monitor influenza activity. In October 2005, a spike in antiviral medication sales was noted. The spike did not coincide with other markers of influenza activity but did coincide with the beginning of media coverage of avian influenza A (H5N1) and the potential for an influenza pandemic. Tracking prescription medication sales can detect spikes for which no immediate indication exists. Such syndromic data might be used to guide issuance of public health recommendations regarding the limited availability of certain medications and the inadvisability of personal stockpiling.</abstract><cop>United States</cop><pub>Centers for Disease Control and Prevention</pub><pmid>16543882</pmid><tpages>3</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0149-2195 |
ispartof | MMWR. Morbidity and mortality weekly report, 2006-03, Vol.55 (10), p.277-279 |
issn | 0149-2195 1545-861X |
language | eng |
recordid | cdi_proquest_miscellaneous_67756339 |
source | JSTOR Archival Journals and Primary Sources Collection; ProQuest Social Science Premium Collection |
subjects | Anti-infective agents Antiviral Agents - supply & distribution Antiviral Agents - therapeutic use Antivirals Commerce Drug prescriptions Drug Utilization - statistics & numerical data Health aspects Humans Influenza Influenza A virus Influenza, Human - epidemiology Influenza, Human - prevention & control Medicaid Medications New York City - epidemiology Pharmacies Population Surveillance Public health Recommendations Seasons Specimens Statistics Surveillance |
title | Increased Antiviral Medication Sales Before the 2005–06 Influenza Season — New York City |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T10%3A00%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Increased%20Antiviral%20Medication%20Sales%20Before%20the%202005%E2%80%9306%20Influenza%20Season%20%E2%80%94%20New%20York%20City&rft.jtitle=MMWR.%20Morbidity%20and%20mortality%20weekly%20report&rft.au=Miller,%20J&rft.aucorp=Centers%20for%20Disease%20Control%20and%20Prevention%20(CDC)&rft.date=2006-03-17&rft.volume=55&rft.issue=10&rft.spage=277&rft.epage=279&rft.pages=277-279&rft.issn=0149-2195&rft.eissn=1545-861X&rft_id=info:doi/&rft_dat=%3Cgale_proqu%3EA144294386%3C/gale_proqu%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-g254t-224fe362a56e436cb4dba6197eea15ba3d477ccb1b9d16cddd84d08051c71b823%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=67756339&rft_id=info:pmid/16543882&rft_galeid=A144294386&rft_jstor_id=23316882&rfr_iscdi=true |